Nektar Therapeutics (NKTR)
NASDAQ: NKTR
· Real-Time Price · USD
60.55
0.05 (0.08%)
At close: Oct 03, 2025, 3:59 PM
60.00
-0.91%
After-hours: Oct 03, 2025, 07:36 PM EDT
0.08% (1D)
| Bid | 52.01 |
| Market Cap | 1.15B |
| Revenue (ttm) | 74.93M |
| Net Income (ttm) | -122.27M |
| EPS (ttm) | -8.93 |
| PE Ratio (ttm) | -6.78 |
| Forward PE | -5.11 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 68.39 |
| Volume | 773,112 |
| Avg. Volume (20D) | 1,020,871 |
| Open | 61.00 |
| Previous Close | 60.50 |
| Day's Range | 57.51 - 61.00 |
| 52-Week Range | 6.45 - 61.79 |
| Beta | 1.20 |
| Ex-Dividend Date | n/a |
About NKTR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NKTR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NKTR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNektar Therapeutics is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+15.06%
Nektar Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
3 months ago
+156.29%
Nektar Therapeutics shares are trading higher after the company announced data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.
